Osimertinib combined bevacizumab in epidermal growth factor receptor T790M-positive non-small-cell lung cancer patients with malignant pleural and/or pericardial effusion who progressed during prior EGFR-TKI treatment -phase II trial-

Trial Profile

Osimertinib combined bevacizumab in epidermal growth factor receptor T790M-positive non-small-cell lung cancer patients with malignant pleural and/or pericardial effusion who progressed during prior EGFR-TKI treatment -phase II trial-

Recruiting
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Osimertinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms SPIRAL II Study
  • Most Recent Events

    • 06 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top